CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...

Cardiovascular disease continues to be the leading cause of death worldwide. But advances in heart-failure therapeutics have ...

Young people’s risk of developing myocarditis is higher and longer lasting after covid-19 infection than after vaccination against it, the largest study of its kind suggests.1 The research—based on ...

The health impact of a Covid infection was higher than the risks from the vaccine for teens and children - but it won't ...

Children and young people have higher risks of rare vascular and inflammatory diseases up to 12 months after a first COVID-19 ...

A large-scale MIT screen of tuberculosis proteins revealed several possible antigens that could be developed as a new vaccine for TB, the world’s deadliest infectious disease.

"We know that repeated infection with COVID-19 is common for children, and this study has added to the evidence that these ...

Ribonucleic acid (RNA) is one of life's most versatile molecules, with roles going far beyond being a messenger of genetic ...

Moderna (MRNA) just began dosing patients in a Phase 1/2 study of mRNA-2808, its experimental T-cell therapy for advanced multiple myeloma. This effort highlights Moderna's growing emphasis on cancer ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the publication of two studies demonstrating the Afirma GRID (Genomic Resource for Intelligent Discovery) research ...

The start of the trial marks an expansion of the firm's oncology pipeline, and the firm hopes mRNA-2808 will be the first of many T-cell engagers in its portfolio.